Streetbeat News

Stock Prices

HAIL

HMC

Honda Motor Company (NYSE:HMC) is recalling 1.7 million vehicles due to a defect in the steering gearbox, causing increased friction and potential crash risks. This follows previous recalls for airbag and fire risks. HMC shares are down 1.72% premarket.

Portfolio Pulse from Lekha Gupta

October 09, 2024 | 12:55 pm

XPON

Trading for XPON was halted and has now resumed as of 8:55:00 AM ET. The halt was due to pending news, and trading has now resumed following the release of this information.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:55 pm

MAXN

Trading for MAXN was halted and has now resumed as of 8:55:00 AM ET. This update is crucial for investors tracking the stock's movements.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:55 pm

ALCE

Alternus Clean Energy's shares fell following the announcement of a 1-for-25 reverse stock split, a move aimed at meeting Nasdaq compliance requirements.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:53 pm

CLSD

Clearside Biomedical's shares rose following the successful results of its ODYSSEY Phase 2b trial for CLS-AX in treating Neovascular age-related macular degeneration, achieving both primary and secondary outcomes.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:52 pm

DWTX

Trading for DWTX was halted and has now resumed as of 8:50:00 AM ET. The halt was due to pending news, and trading has now resumed following the release of this information.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:50 pm

LUXH

LuxUrban Hotels' shares are declining following the company's filing of a prospectus to sell up to 23.63 million shares of common stock.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:49 pm

NISN

NiSun International Enterprise shares are rising following the company's announcement of expected record revenue for the first half of 2024.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:46 pm

UCAR

U Power Limited shares are experiencing a decline, potentially due to ongoing weakness after the release of its H1 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:44 pm

CANF

Can-Fite Biopharma's shares rose following the FDA's orphan drug designation for its drug namodenoson, aimed at treating pancreatic cancer.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:40 pm